7 research outputs found
Multivariable analysis including patients within 3 hours of symptom onset (n = 197).
<p>Clinical model: Age, sex, hypertension, hypercholesterolemia, family history of CVD, current and former smoking, diabetes mellitus, and history of MI, PCI or CABG, and ECG. Abbreviations: hs-cTnT, high-sensitive cardiac troponin; PlGF, placental growth factor; sFlt-1, soluble Fms-like tyrosine kinase-1; NT-proBNP, N-terminal prohormone B-type Natriuretic Peptide; GDF-15, growth differentiation factor-15; AUC, area under the receiver operating curve (ROC); CI, confidence interval.</p><p>*adjusted for over-optimism</p><p>** compared to the Clinical model</p><p>*** compared to the Clinical model + hs-cTnT</p><p>Multivariable analysis including patients within 3 hours of symptom onset (n = 197).</p
Sensitivity, specificity, predictive values and AUCs of hs-cTnT, myoglobin and 5 novel biomarkers in patients with symptom onset within 3 hours.
<p>Values are given as percentage or number (95%CI)</p><p>Abbreviations: hs-cTnT, high-sensitive cardiac troponin; PlGF, placental growth factor; sFlt-1, soluble Fms-like tyrosine kinase-1; NT-proBNP, N-terminal prohormone B-type Natriuretic Peptide; GDF-15, growth differentiation factor-15; PPV, positive predictive value; NPV, negative predictive value; AUC, area under the receiver operating curve (ROC).</p><p>Sensitivity, specificity, predictive values and AUCs of hs-cTnT, myoglobin and 5 novel biomarkers in patients with symptom onset within 3 hours.</p
Receiver-operating-characteristic curves of the clinical model with the various biomarkers, high sensitive cardiac troponin T (hs-cTnT), placental growth factor (PlGF), fms-like tyrosine kinase-1 (sFlt-1), myoglobin, N-terminal prohormone B-type Natriuretic Peptide (NT-proBNP), growth differentiation factor-15 (GDF-15) and copeptin.
<p>(The ROC curve shown is from the first imputation set)</p
Median biomarker concentrations and inter quartile ranges stratified by ACS status.
<p>Values are given as median (Inter Quartile Range); p-value calculated with Mann-Whitney <i>U</i>-test</p><p>Abbreviations: hs-cTnT, high-sensitive cardiac troponin; PlGF, placental growth factor; sFlt-1, soluble Fms-like tyrosine kinase-1; NT-proBNP, N-terminal prohormone B-type Natriuretic Peptide; GDF-15, growth differentiation factor-15.</p><p>Median biomarker concentrations and inter quartile ranges stratified by ACS status.</p
Flow chart of patient selection from all patients with symptoms suggestive of ACS to enrolled patients.
<p>Flow chart of patient selection from all patients with symptoms suggestive of ACS to enrolled patients.</p
Multivariable analysis including all patients (n = 453).
<p>Clinical model: Age, sex, hypertension, hypercholesterolemia, family history of CVD, current and former smoking, diabetes mellitus, and history of MI, PCI or CABG and ECG. Abbreviations: hs-cTnT, high-sensitive cardiac troponin; PlGF, placental growth factor; sFlt-1, soluble Fms-like tyrosine kinase-1; NT-proBNP, N-terminal prohormone B-type Natriuretic Peptide; GDF-15, growth differentiation factor-15; AUC, area under the receiver operating curve (ROC); CI, confidence interval.</p><p>*adjusted for over-optimism</p><p>** compared to the Clinical model</p><p>*** compared to the Clinical model + hs-cTnT</p><p>Multivariable analysis including all patients (n = 453).</p
Baseline characteristics stratified by time of presentation after symptom onset.
<p>Values are given as mean (±Standard Deviation), median (IQR = Inter Quartile Range) or proportion (%)</p><p>Abbreviations: CVD, cardiovascular disease; BMI, body mass index; CVA, cerebrovascular accident; TIA, transient ischemic attack; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft.</p><p>Baseline characteristics stratified by time of presentation after symptom onset.</p